GlassScriptPhysician profile
Irving Michael Bratt
NPI 1669461687
$5,504.08
in general payments reported to CMS, 2019-2025
44 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $273 · 2021: $572 · 2022: $693 · 2023: $974 · 2024: $1,082 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.30 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,531.18 | 2019-2025 | |
| Pfizer INC. | $579.00 | 2019-2025 | |
| Astellas Pharma US INC | $332.94 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $300.78 | 2019-2025 | Breztri, Airsupra |
| Abbott Laboratories | $292.80 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Amgen INC. | $259.15 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $208.58 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $206.12 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $177.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.36 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $130.50 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $126.34 | 2019-2025 | Synthroid |
| Takeda Pharmaceuticals U.S.A., INC. | $119.74 | 2019-2022 | |
| Viiv Healthcare Company | $118.27 | 2022-2025 | Apretude |
| Amarin Pharma, INC. | $115.66 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irving Bratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.